Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: Results from the US Lymphoma CAR T Consortium

Researchers found the efficacy and toxicity of brexucabtagene autoleucel (brexu-cel) in the standard-of-care setting to be consistent with those reported in the ZUMA-2 trial, on which brexu-cel approval was based. Individual tumor-intrinsic features of relapsed/refractory mantle cell lymphoma, and possibly recent bendamustine exposure, were found to be possible associations with inferior efficacy outcomes.